Clinical trials: Renal Transplanted Recipients
Antibody-Mediated Rejection (AMR)
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure.
- Trial name
- NCT07613359
- Testing
- Mezagitamab
- Where
- 35 sites in United States, China and 3 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Medication Adherence
Medication Adherence in Kidney Transplant Patients: SystemCHANGE™ Results of the Turkish MAGIC Randomized Clinical Trial
The SystemCHANGETM intervention harnesses patients' established daily routines/habits, environment, and important others, as possible solutions that are reoccurring and thus reliable systems that could support medication taking…
- Trial name
- NCT06106854
- Testing
- Behavioral: SystemCHANGE, Education
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Dokuz Eylul University
BK Virus Infection
Ciprofloxacin for Prevention of BK Infection
BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower…
- Trial name
- NCT01789203
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplant Infection, Bloodstream Infection
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs).
- Conditions
- Kidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant Recipients
- Trial name
- PREDICT (NCT07407673)
- Testing
- Pivmecillinam
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Kidney Transplant
Natural History Study of Azathioprine Adherence
This study began in 1993 as a prospective, natural history study of renal transplant patients' medication compliance measured by using an electronic monitor on the cap of medication vials.
- Trial name
- NCT00143910
- Testing
- observation
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Thomas E. Nivens, MD
Medication Adherence, Transplant; Kidney
A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
The investigators are interested in whether or not the use of a mobile health (mHealth) application increases the rate of immunosuppression medication adherence among adult kidney transplant recipients.
- Trial name
- mDOT (NCT03427008)
- Testing
- mHealth Intervention
- Where
- United States
- Sponsor
- Johns Hopkins University
Antibody-mediated Rejection in Kidney Transplant
Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
- Trial name
- NCT05452317
- Testing
- Chronic active AMR group, Non-Chronic active AMR group
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- CSL Behring
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Kidney Transplant; Complications
Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients
The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to…
- Trial name
- NCT03036748
- Testing
- Standardized sodium diet, Tbl amiloride
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- University of Southern Denmark
De Novo Kidney Transplant Recipients
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
This trial is designed to assess the efficacy, tolerability, and safety of EC-MPS in combination with cyclosporine microemulsion (CsA-ME) with or without steroids in kidney transplant recipients.
- Trial name
- NCT00312143
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 35 people
- Sponsor
- Novartis
End Stage Renal Disease
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Regulatory CD4+CD25+ T cells (Treg) derived from the thymus and/or peripheral tissues have been demonstrated to broadly control T cell reactivity (14).
- Trial name
- TRACT (NCT02145325)
- Testing
- Expanded Tregs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
End Stage Renal Disease
Myfortic vs. Cellcept in Kidney Transplant Recipients
The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal…
- Trial name
- NCT00533624
- Testing
- Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Miami
Kidney Transplantation
Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients
The purpose of this study is to test noninvasive methods to monitor the health and condition of new kidneys in people who have received kidney transplants.
- Trial name
- NCT00308802
- Testing
- Kidney transplantation
- Where
- 9 sites in United States, Canada
- Volunteers
- 280 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients
This study evaluated renal graft function based on calculated creatinine clearance at 6 months after transplantation in patients receiving a regimen of 'reduced' or 'standard' dose tacrolimus plus sirolimus and corticosteroids.
- Trial name
- NCT00518271
- Testing
- Rapamune® (Sirolimus), Tacrolimus, Corticosteroids
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Kidney Transplantation
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response.
- Trial name
- NCT02576145
- Testing
- DT, Daclizumab, KLH
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Failure With Renal Transplant
Study of Everolimus in de Novo Renal Transplant Recipients
In the present study, the investigators propose a conversion scheme with 50% reduction in CNI dosage until adjustment of everolimus dosage, in order to reach a trough blood level of 6-10 ng/mL, thus avoiding overimmunosuppression…
- Trial name
- NCT01609673
- Testing
- Everolimus
- Where
- 4 sites in Brazil
- Volunteers
- 1 people
- Sponsor
- Helady Pinheiro, MD, PhD
Real Function Post Conversion From Prograf to Advagraf, Examin Ethnicity and Pharmacogenetics of the Cohort Requiring Dose Adjustment Post-conversion
Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD
In Kidney transplant recipients Once daily Tacrolimus has the poteb]ntial advantage of better adnerence, and perhpas improvement in reanl function compred with the twice daily tacrolimus formulation.
- Trial name
- NCT01884480
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Unity Health Toronto
Liver Transplant, Renal Transplant
Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses
Liver/renal transplantations are now tending to be the most important treatment for terminal liver and renal disease. Although transplantation can prevent recipients from suffering with critical and fatal symptoms, patients may…
- Trial name
- NCT01380002
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital